AFP

Product List

Creative Biolabs supply extensive range of anti-AFP CAR related products and one-stop solution to support our clients’ CART development. Please browse the following list to find the products you need.

Background

Alpha-fetoprotein (AFP) is a tumor-associated fetal mammalian glycoprotein involved in a variety of biological processes, including regulation of cell proliferation, migration, apoptosis, immune escape, and induction of malignant transformation of cancer cells. Studies have shown that AFP is closely related to the occurrence of a variety of tumors, and can be used as a clinical biomarker and prognostic indicator for the diagnosis of carcinomas.

Fig.1 Schematic diagram of AFP binding to AFP receptors promoting malignant transformation of cancer cells.¹

Associated Diseases

• Liver tumor
• Hepatocellular carcinoma
• Others

Anti-AFP CAR-T Services

Anti-AFP CAR-T In Vitro Assays

Anti-AFP CAR-T Expression Test

Creative Biolabs has developed multiple CAR detection reagents (such as target-specific CAR detection reagents, linker-specific antibodies), and established various approaches to test CAR expression.

Anti-AFP CAR-T Phenotype Analysis

To characterize the capability of AFP-CAR T cells, Creative Biolabs has developed a comprehensive phenotypic assessment service to test the proliferation, stimulation, and degranulation activity of CART cells. For anti-AFP CAR-T phenotype analysis, CD107a surface expression as a measurement marker to test the degranulation activity by flow cytometry.

Fig.2 CD107a expression detection of AFP-CAR+ CD8+ T cells incubated with different tumor cells at 5:1 E:T ratio by flow cytometry.²

Anti-AFP CAR-T Cytokine Release Test

To assess the cytokine releasing capability of CART cells co-cultured with target cells, we supply many suitable approaches for cytokine detection, such as multiplex cytokine array, and intracellular cytokine test by flow cytometry.

Multiplex ELISA to test cytokine secretion

Fig.3 Cytokine secretion measurements of AFP CAR-T cells co-cultured with different tumor cells by multiplex ELISA.²

Flow cytometry analysis to assess intracellular cytokine

Fig.4 Cytokine measurements of AFP CAR-T cells co-cultured with different tumor cells detected by intracellular staining.²

Anti-AFP CAR-T In Vitro Cytotoxicity Assay

We offer a variety of robust and sensitive methods to evaluate the antigen specificity and antitumor activity of CART cells incubated with target cells, including but not limited to LDH release assay, real-time cell analysis (RTCA), and cytotoxicity test by flow cytometry.

Fig.5 The cytotoxicity evaluation of AFP CAR-T cells against target A2+/AFP+ cells at 5:1 E:T ratio detected by LDH release assay.²

Anti-AFP CAR-T In Vivo Assays

Anti-AFP CAR-T Cell Therapy Animal Models

Creative Biolabs is committed to providing one-stop services for CART development, including in vivo related items, such as off-the-shelf and customized animal models, as well as optimized in vivo experimental design.

Efficacy Test of Anti-AFP CAR-T

To assess the in vivo antitumor activity of CAR T cells in appropriate animal models, Creative Biolabs provides optimized experimental design and detection solutions for global customers to support CAR development. For all in vivo experiments, we test each batch of CART cells in an in vitro cytotoxicity assay to ensure batch-to-batch with low variation before in vivo administration.

Fig.6 The antitumor evaluation of anti-AFP CAR-T in the disseminated peritoneal liver cancer model detected by luciferase photon emission.²

Toxicity Evaluation Anti-AFP CAR-T

To monitor and evaluate the safety of CART treatment, we have launched a comprehensive range of evaluation solutions for target-specific CART projects. Our robust CAR-T evaluation services include, but are not limited to, tissue phenotype analysis of in vivo models with CART treatment, and off-toxicity studies.

References

1. Lin, Bo, et al. "Alpha-fetoprotein binding mucin and scavenger receptors: an available bio-target for treating cancer." Frontiers in Oncology 11 (2021): 625936.
2. Liu, Hong, et al. "Targeting alpha-fetoprotein (AFP)–MHC complex with CAR T-cell therapy for liver cancer." Clinical cancer research 23.2 (2017): 478-488.